SCHEMBL733348

SCHEMBL733348

CC(=O)C(C)C(=O)SN1C(=O)CCC1=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1269711 0.81
SCHEMBL5929267 0.74 GLA (0.33)
SCHEMBL1541732 0.65 MGLL (0.33)
SCHEMBL863100 0.65 MGLL (0.33)
SCHEMBL18020563 0.64 SLC1A2 (0.45)
SCHEMBL3468975 0.64 MEN1 (0.30)
SCHEMBL11588858 0.63 PIK3CD (0.31)
SCHEMBL43849 0.61 SLC1A2 (0.40)
SCHEMBL7019667 0.60
SCHEMBL93292 0.59

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 171 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2010078376-A2 FC-SPECIFIC POLYMER-CONJUGATED ANTIBODIES AND THEIR DIAGNOSTIC USE VENTANA MEDICAL SYSTEMS, INC. (US) 2010-07-08 WO claimed
EP-0382781-B1 COMPOSITION FOR TREATING CANCERS CHARACTERIZED BY OVER-EXPRESSION OF THE C-FMS PROTO-ONCOGENE GENETICS INSTITUTE, INC. (US) 1993-09-29 EP claimed
US-20260109728-A1 IMMUNOMODULATING POLYNUCLEOTIDES, ANTIBODY CONJUGATES THEREOF, AND METHODS OF THEIR USE TALLAC THERAPEUTICS INC (US) 2026-04-23 US disclosed
US-12351598-B2 Immunomodulating polynucleotides, antibody conjugates thereof, and methods of their use Tallac Therapeutics, Inc. (US) 2025-07-08 US disclosed
US-12280021-B2 Affinity medicant conjugate AF CHEMICALS, LLC (US) 2025-04-22 US disclosed
EP-4257186-B1 AFFINITY MEDICANT CONJUGATES AF CHEMICALS LLC (US) 2024-12-04 EP disclosed
US-20230372267-A1 AFFINITY MEDICANT CONJUGATE Califia Pharma Inc. (US) 2023-11-23 US disclosed
EP-4257186-A2 AFFINITY MEDICANT CONJUGATES AF Chemicals LLC (US) 2023-10-11 EP disclosed
EP-3129357-B1 AFFINITY MEDICANT CONJUGATES AF CHEMICALS LLC (US) 2023-08-23 EP disclosed
US-11359185-B2 Antibody conjugates VENTANA MEDICAL SYSTEMS, INC. (US) 2022-06-14 US disclosed
US-20220056069-A1 IMMUNOMODULATING POLYNUCLEOTIDES, ANTIBODY CONJUGATES THEREOF, AND METHODS OF THEIR USE HORIZON TECHNOLOGY FINANCE CORPORATION 2022-02-24 US disclosed
WO-2002082078-A2 ACTIVATED ENZYME-LINKED DETECTION SYSTEMS FOR DETECTING AND QUANTIFYING NUCLEID ACIDS, ANTIGENS ANTIBODIES AND OTHER ANALYTES FRAUNHOFER-GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V. (DE) 2002-10-17 WO disclosed
WO-2002081739-A2 NON-ENZYMATIC LIPOSOME-LINKED CLOSELY SPACED ARRAY ELECTRODES ASSAY (NEL-ELA) FOR DETECTING AND QUANTIFYING NUCLEIC ACIDS Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) 2002-10-17 WO disclosed
WO-2002081738-A2 SYSTEM AND METHOD FOR DETECTING AND QUANTIFYING NUCLEIC ACIDS USING COVALENT BINDING FRAUNHOFER-GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V. (DE) 2002-10-17 WO disclosed
US-20020048598-A1 INTERNALLY SUPPORTED LIPID VESICLE SYSTEMS MALIK NAVID (GB) 2002-04-25 US disclosed
US-20020006623-A1 Compositions and methods for array-based genomic nucleic acid analysis of biological molecules NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2002-01-17 US disclosed
WO-2001041827-A1 INTERNALLY SUPPORTED BIOMIMETIC MATERIALS AND COATINGS MALIK NAVID (GB) 2001-06-14 WO disclosed
EP-0998267-A1 INTERNALLY SUPPORTED LIPID VESICLE SYSTEMS Malik, Navid (GB) 2000-05-10 EP disclosed
WO-1998056353-A1 INTERNALLY SUPPORTED LIPID VESICLE SYSTEMS MALIK NAVID (GB) 1998-12-17 WO disclosed
EP-0382781-B1 COMPOSITION FOR TREATING CANCERS CHARACTERIZED BY OVER-EXPRESSION OF THE C-FMS PROTO-ONCOGENE GENETICS INSTITUTE, INC. (US) 1993-09-29 EP disclosed